Immediate Impact
10 standout
Citing Papers
Targeting cytokine and chemokine signaling pathways for cancer therapy
2024 Standout
Immunologic tumor microenvironment modulators for turning cold tumors hot
2024 Standout
Works of Noel Laudi being referenced
E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma
2018
A randomized phase II study of ipilimumab at 3 (ipi3) or 10 mg/kg (ipi10) alone or in combination with high dose interferon-alfa (HDI) in advanced melanoma (E3611).
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Noel Laudi | 43 | 35 | 13 | 13 | 6 | 55 | |
| R. Andrew Harkins | 25 | 40 | 8 | 17 | 7 | 64 | |
| Nurgul Kilavuz | 47 | 27 | 17 | 7 | 6 | 55 | |
| Dan Kristensen | 35 | 39 | 17 | 33 | 6 | 83 | |
| Simon Rule | 26 | 32 | 6 | 18 | 7 | 51 | |
| Lanie E. Happ | 18 | 17 | 11 | 9 | 9 | 40 | |
| Amanda Gillespie-Twardy | 22 | 23 | 4 | 17 | 6 | 42 | |
| Valentina Bonuomo | 22 | 13 | 9 | 8 | 7 | 48 | |
| Sandra Le Guyader-Peyrou | 38 | 54 | 4 | 32 | 5 | 74 | |
| Ria Uhlig | 43 | 12 | 23 | 12 | 6 | 75 | |
| Lukas Kazianka | 21 | 26 | 6 | 4 | 9 | 48 |
All Works
Login with ORCID to disown or claim papers
Loading papers...